Why does it take almost ten years and tens of thousands of dollars to get diagnosed with vulvo-vaginal pain - and why is an entire industry now profiting from that gap?
Carmen Rising is a journalist who covers vulvo-vaginal and pelvic pain, with recent pieces in The New York Times and The Guardian. She came to the subject the hard way, spending almost a decade trying to get a proper diagnosis for her own vulvo-vaginal pain before turning that experience into reporting on the systems that keep failing women. In this episode, she and Mathilde unpack the real financial cost of chronic pelvic pain, why insurance keeps letting patients down, and how an unregulated wellness industry has stepped in to fill the gap left by medicine.
The real cost of vulvodynia: why diagnosis takes years and thousands of dollars
Carmen's reporting puts a number on something most women with chronic pelvic pain already feel in their bank balance: getting diagnosed and treated for conditions like vulvodynia and vestibulodynia is punishingly expensive. One study she cites puts the national economic burden between thirty-one and seventy-two billion dollars a year, and that figure is from 2012, so the real number today is almost certainly higher. For individual patients, the costs she quotes in her reporting range from fifteen thousand to forty thousand dollars, often before a diagnosis is even confirmed.
Most of that cost comes from the diagnostic delay itself. Patients see an average of eight providers before reaching a specialist, and every appointment adds up: time off work, childcare, parking, co-pays, and treatments that turn out to be the wrong ones. Specialists in vulvo-vaginal pain and pelvic floor dysfunction frequently operate outside insurance altogether, which pushes the cash cost even higher for people who are already exhausted from years of searching for answers.
There's such a life, not just an economic burden, but a quality of life burden that goes with that.
Why the insurance system fails women with chronic pelvic pain
A lot of this comes down to how insurance is structured. Appointments are typically capped at around fifteen minutes, which is workable for something straightforward but nowhere near enough time to untangle a case of chronic pelvic pain that might involve hormonal, muscular, and neurological factors all at once, including conditions like pudendal neuralgia or pelvic floor dysfunction. Carmen also points out that some vulvo-vaginal pain diagnoses do not even have a billing code, which in practical terms means insurers are treating certain conditions as though they do not exist.
The reimbursement structure compounds the problem. Carmen notes that a hysterectomy is reimbursed at one of the lowest rates of any surgery, while procedures like knee replacements pay doctors far more for comparable time and complexity. That imbalance shapes which conditions specialists are financially able to focus on, and it is a major reason so many pelvic floor therapy and pain specialists end up working outside the insurance system entirely, leaving patients to pay out of pocket for care that should be a basic medical entitlement.
You can make more money as a doctor by doing a knee replacement than you can as a doing a hysterectomy.
The vaginal wellness industry: profiting from a broken system?
Where medicine has been slow, the wellness industry has moved fast. Carmen's New York Times piece traces a boom in direct-to-consumer products marketed at women with vulvo-vaginal pain, sexual health concerns, and painful sex, many carrying vague labels like "OBGYN-backed" or "evidence-based" that sound clinical without actually meaning very much. She describes being targeted with ads for balms, pills, and supplements making diagnostic-sounding claims, sometimes aimed at teenagers desperately searching for relief from conditions like dyspareunia.
Vaginal microbiome test kits are a clear example of the pattern. Several companies use the same manufacturer's PCR swab, repackage it, and sell it on subscription, often without any medical guidance on how to interpret the results. The swab itself can be genuinely useful, but as Carmen explains, a single test gives an incomplete picture of a microbiome that fluctuates constantly, and the companies selling these kits operate entirely outside any regulatory system, making health claims with no one checking whether they hold up.
As long as medicine, Western medicine continues to fail women, industry will fill its gaps.
What women with pelvic pain and painful sex can do right now
Carmen's reporting is not an argument to distrust every wellness product, but it is a case for reading labels carefully and treating marketing language with scepticism. A product being "OBGYN-backed" costs a company very little to claim and means almost nothing on its own. If a product or test kit makes a diagnostic claim, it is worth asking who regulates that claim, and whether the people selling it are also the people set up to help you interpret the result. That is especially true for anyone managing chronic pelvic pain or pelvic floor dysfunction, where the right next step often depends on ruling things in or out with an actual clinician, not a subscription box.
The bigger fix, as Carmen argues, is systemic: medical students and general practitioners need basic training in vulvo-vaginal pain so patients are not left to become their own diagnosticians over a decade of trial and error. Grassroots efforts like Tightlipped and Stephanie Berman's Aziza Project, which helps patients afford specialist care, are doing important work, but they cannot replace a functioning system. Supporting that kind of advocacy, and pushing for pelvic health and pelvic floor therapy to be treated as core medical knowledge rather than a niche specialty, is where real, lasting change starts.
